ReviewNature reviews. Urology2022
The current role of MRI for guiding active surveillance in prostate cancer.
Review in Nature reviews. Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.BJU international · 2026Trial
- Trial
- Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.European radiology · 2026Article
- 5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance.Prostate cancer and prostatic diseases · 2026Article
- Evaluation of the Proliferation Marker Ki-67 for Improved Risk Stratification of Prostate Cancer Patients Under Active Surveillance.Diagnostics (Basel, Switzerland) · 2026Article
- Prostate specific membrane antigen (PSMA) as a biomarker in early and localized advanced prostate cancer: a narrative review.The Canadian journal of urology · 2026Review
- Article
- Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.JAMA network open · 2025Article
- Is MRI ready to replace biopsy during active surveillance?European radiology · 2024Review
- The role of the radiologist in the prostate cancer multidisciplinary conference.Abdominal radiology (New York) · 2024Review
- Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study.European urology open science · 2024Article
- Exploring the relation of active surveillance schedules and prostate cancer mortality.Cancer medicine · 2024Article
- MRI-derived PRECISE score for predicting pathologically-confirmed progression in prostate cancer patients on active surveillance.Central European journal of urology · 2024Article
- Progress of fluorescence imaging in lymph node dissection surgery for prostate and bladder cancer.Frontiers in oncology · 2024Review
- A Narrative Review of the Use of Artificial Intelligence in Breast, Lung, and Prostate Cancer.Life (Basel, Switzerland) · 2023Review
- Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.European urology open science · 2023Article
- The Impact of Multiparametric Magnetic Resonance Imaging on Treatment Strategies for Incidental Prostate Cancer after Holmium Laser Enucleation of the Prostate.Journal of clinical medicine · 2023Article
- Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.European radiology · 2023Article
- Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach.World journal of urology · 2023Article
- Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications.European journal of nuclear medicine and molecular imaging · 2023Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active surveillance (AS) is the recommended treatment option for low-risk and favourable intermediate-risk prostate cancer management, preserving oncological and functional outcomes. However, active monitoring using relevant parameters in addition to the usual clinical, biological and pathological considerations is necessary to compensate for initial undergrading of the tumour or to detect early progression without missing the opportunity to provide curative therapy. Indeed, several studies have raised concerns about inadequate biopsy sampling at diagnosis. However, the implementation of baseline MRI and targeted biopsy have led to improved initial stratification of low-risk disease; baseline MRI correlates well with disease characteristics and AS outcomes. The use of follow-up MRI during the surveillance phase also raises the question of the requirement for serial biopsies in the absence of radiological progression and the possibility of using completely MRI-based surveillance, with triggers for biopsies based solely on MRI findings. This concept of a tailored-risk, imaging-based monitoring strategy is aimed at reducing invasive procedures. However, the abandonment of serial biopsies in the absence of MRI progression can probably not yet be recommended in routine practice, as the data from real-life cohorts are heterogeneous and inconclusive. Thus, the evolution towards a routine, fully MRI-guided AS pathway has to be preceded by ensuring quality programme assessment for MRI reading and by demonstrating its safety in prospective trials.
Indexed as
Identifiers
35393568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.